5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 17 points (-0.1%) at 12,949 as of Tuesday, Nov. 27, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,707 issues advancing vs. 1,183 declining with 148 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.0%. A company within the industry that fell today was Life Technologies ( LIFE), up 1.0%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Services industry lower today. As of noon trading, DaVita HealthCare Partners is down $0.84 (-0.8%) to $109.16 on heavy volume Thus far, 661,966 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 868,400 shares. The stock has ranged in price between $108.84-$110.42 after having opened the day at $110.18 as compared to the previous trading day's close of $110.00.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $10.6 billion and is part of the health care sector. The company has a P/E ratio of 20.2, above the S&P 500 P/E ratio of 17.7. Shares are up 47.0% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full DaVita HealthCare Partners Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy It Like Buffett -- or Better

Buy It Like Buffett -- or Better